Juan Jesús
Gómez-Reino Carnota
Sociedad Española de Reumatología
Madrid, EspañaPublicacións en colaboración con investigadores/as de Sociedad Española de Reumatología (24)
2019
-
Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry
Rheumatology International, Vol. 39, Núm. 3, pp. 509-515
-
Objectives and methodology of BIOBADASER phase III
Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236
-
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1536-1544
2018
-
Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER
Arthritis Research and Therapy, Vol. 20, Núm. 1
-
Status of Rheumatology in Spain in 2017: 2.0 Rheumatologists per 100,000 Population
Reumatologia Clinica
2015
-
Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294
2013
-
Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico
Reumatologia Clinica, Vol. 9, Núm. 5, pp. 281-296
-
Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: Study using the spanish registry of adverse events of biological therapies in rheumatic diseases
Arthritis Care and Research, Vol. 65, Núm. 12, pp. 2024-2031
2012
-
Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the Spanish registry BIOBADASER 2.0
Annals of the Rheumatic Diseases, Vol. 71, Núm. 3, pp. 382-385
-
Infections in patients with rheumatic diseases treated with TNF antagonists
Current Pharmaceutical Biotechnology, Vol. 13, Núm. 8, pp. 1418-1425
2011
-
Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists
Seminars in Arthritis and Rheumatism, Vol. 41, Núm. 1, pp. 71-80
-
Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
Seminars in Arthritis and Rheumatism, Vol. 40, Núm. 4, pp. 330-337
-
Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
Seminars in Arthritis and Rheumatism, Vol. 41, Núm. 3, pp. 524-533
-
Infecciones en pacientes tratados con antagonistas del factor de necrosis tumoral: incidencia, etiología y mortalidad en el registro BIOBADASER
Medicina Clinica, Vol. 137, Núm. 12, pp. 533-540
-
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
Rheumatology, Vol. 50, Núm. 1, pp. 85-92
2010
-
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755
-
Recommendations for the management of influenza A (H1N1) in rheumatic patients with immunosuppression
Reumatologia Clinica, Vol. 6, Núm. 1, pp. 63-68
2007
-
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
Annals of the Rheumatic Diseases, Vol. 66, Núm. 7, pp. 880-885
-
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection
Arthritis Care and Research, Vol. 57, Núm. 5, pp. 756-761
2006
-
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
Arthritis Research and Therapy, Vol. 8, Núm. 3